A Switch To ViiV's Two-Drug Dovato Keeps HIV Suppressed

Top-line results from the Phase III TANGO study suggests that switching to ViiV’s two-drug Dovato from a three-drug regimen does not affect the efficacy of treatment.

Dancing
A two-drug combo in TANGO is effective • Source: Shutterstock

ViiV Healthcare ’s new single-pill, two-drug HIV therapy, Dovato (dolutegravir/lamivudine), has met its primary endpoint in the Phase III TANGO study, indicating that levels of HIV continue to be suppressed after patients are switched from a TAF-containing three-drug regimen, the company announced on 10 July.

The TANGO study met the primary endpoint for non-inferiority of the two-drug versus three-drug regimen, based on the proportion of...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip